167 related articles for article (PubMed ID: 34741082)
41. Hepatic sinusoidal obstruction syndrome caused by the ingestion of
Cen P; Ding J; Jin J
J Int Med Res; 2021 Apr; 49(4):300060520980649. PubMed ID: 33845617
[TBL] [Abstract][Full Text] [Related]
42. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS).
de la Rubia J; Carral A; Montes H; Urquijo JJ; Sanz GF; Sanz MA
Haematologica; 1996; 81(6):536-9. PubMed ID: 9009442
[TBL] [Abstract][Full Text] [Related]
43. Current role of portosystemic shunt surgery in the management of hepatic venous outflow obstruction.
Singhal D; de Castro S; Goyal N; Gouma DJ; Chaudhary A; van Gulik TM
Dig Surg; 2006; 23(5-6):358-69. PubMed ID: 17164547
[TBL] [Abstract][Full Text] [Related]
44. A TMT-based shotgun proteomics uncovers overexpression of thrombospondin 1 as a contributor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wang W; Chen Y; Yin Y; Wang X; Ye X; Jiang K; Zhang Y; Zhang J; Zhang W; Zhuge Y; Chen L; Peng C; Xiong A; Yang L; Wang Z
Arch Toxicol; 2022 Jul; 96(7):2003-2019. PubMed ID: 35357534
[TBL] [Abstract][Full Text] [Related]
45. Enoxaparin attenuates pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression.
Xiang H; Liu C; Xiao Z; Du L; Wei N; Liu F; Song Y
Liver Int; 2023 Mar; 43(3):626-638. PubMed ID: 36354295
[TBL] [Abstract][Full Text] [Related]
46. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study.
Peng C; Zhang X; Zhang F; Liu L; Shao Y; Xiang X; Zhang W; Xiao J; Wang Y; Zhang B; Yin Q; Song Y; Mo Z; Zou X; Zhang M; Zhuge Y
Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1168-1178. PubMed ID: 31834055
[TBL] [Abstract][Full Text] [Related]
47. Proteomic study of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in rats.
Li YH; Tai WC; Xue JY; Wong WY; Lu C; Ruan JQ; Li N; Wan TF; Chan WY; Hsiao WL; Lin G
Chem Res Toxicol; 2015 Sep; 28(9):1715-27. PubMed ID: 26280871
[TBL] [Abstract][Full Text] [Related]
48. The long persistence of pyrrolizidine alkaloid-derived pyrrole-protein adducts in vivo: Kinetic study following multiple exposures of a pyrrolizidine alkaloid containing extract of Gynura japonica.
Chen Y; Xiong F; Wang W; Jiang K; Ye X; Deng G; Wang C; Yang L; Xiong A; Wang Z
Toxicol Lett; 2020 May; 323():41-47. PubMed ID: 31982501
[TBL] [Abstract][Full Text] [Related]
49. Transjugular liver biopsy after transjugular intrahepatic portosystemic shunt (TIPS) or direct intrahepatic portocaval shunt (DIPS): Is it feasible, effective, and safe?
Kaufman C; Aryafar H; Minocha J; Kinney T
Diagn Interv Imaging; 2018 May; 99(5):331-335. PubMed ID: 29366793
[TBL] [Abstract][Full Text] [Related]
50. Outcomes of combination treatment with MARS and TIPS for hepatic veno-occlusive disease: a report of 12 cases.
Deng L; Yin X; Zhao Y; Yang J; Yang H; Xu C; Li K
J Int Med Res; 2020 Dec; 48(12):300060520980877. PubMed ID: 33372815
[TBL] [Abstract][Full Text] [Related]
51. Transjugular intrahepatic portosystemic shunt for the prevention of recurrent esophageal variceal bleeding in patients with cavernous transformation of portal vein.
Li ZP; Wang SS; Wang GC; Huang GJ; Cao JQ; Zhang CQ
Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):517-523. PubMed ID: 30262421
[TBL] [Abstract][Full Text] [Related]
52. Bear bile powder attenuates senecionine-induced hepatic sinusoidal obstruction syndrome in mice.
Jiang KY; Zhang Y; Ye XL; Xiong F; Chen Y; Jia XL; Zhang YX; Yang L; Xiong AZ; Wang ZT
Chin J Nat Med; 2022 Apr; 20(4):270-281. PubMed ID: 35487597
[TBL] [Abstract][Full Text] [Related]
53. Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features.
Zhou H; Wang YX; Lou HY; Xu XJ; Zhang MM
Korean J Radiol; 2014; 15(2):218-25. PubMed ID: 24643319
[TBL] [Abstract][Full Text] [Related]
54. Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update.
Teschke R; Vongdala N; Quan NV; Quy TN; Xuan TD
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638760
[TBL] [Abstract][Full Text] [Related]
55. Magnetic Resonance Imaging Findings in Patients With Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome.
Li X; Yang X; Xu D; Li Q; Kong X; Lu Z; Bai T; Xu K; Ye J; Song Y
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):955-957. PubMed ID: 28126425
[No Abstract] [Full Text] [Related]
56. Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding.
Xue H; Zhang M; Pang JX; Yan F; Li YC; Lv LS; Yuan J; Palikhe M; Li WZ; Wang ZL
World J Gastroenterol; 2012 Dec; 18(48):7341-7. PubMed ID: 23326143
[TBL] [Abstract][Full Text] [Related]
57. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
[TBL] [Abstract][Full Text] [Related]
58. The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension.
Hassoun Z; Pomier-Layrargues G
Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):1-4. PubMed ID: 15095845
[TBL] [Abstract][Full Text] [Related]
59. Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome.
Liu Z; Liang S; Wei X; Du X; Zhang J
BMC Gastroenterol; 2022 Dec; 22(1):525. PubMed ID: 36526956
[TBL] [Abstract][Full Text] [Related]
60. Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt (TIPS).
Lévy V; Azoulay D; Rio B; Vincent F; Rabbat A; Hunault M; Bazarbachi A; Delmer A; Zittoun R
Bone Marrow Transplant; 1996 Aug; 18(2):443-45. PubMed ID: 8864460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
